| 000 | 01887 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514075910.0 | ||
| 264 | 0 | _c20050209 | |
| 008 | 200502s 0 0 eng d | ||
| 022 | _a0961-2033 | ||
| 024 | 7 |
_a10.1191/0961203303lu430oa _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrunner, H I | |
| 245 | 0 | 0 |
_aLupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage. _h[electronic resource] |
| 260 |
_bLupus _c2003 |
||
| 300 |
_a600-6 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Antiphospholipid _xdrug effects |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild Welfare |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHeadache _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xcomplications |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNarcotics _xtherapeutic use |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 |
_aPrednisone _xtherapeutic use |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aSickness Impact Profile |
| 650 | 0 | 4 | _aStatistics as Topic |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 700 | 1 | _aJones, O Y | |
| 700 | 1 | _aLovell, D J | |
| 700 | 1 | _aJohnson, A M | |
| 700 | 1 | _aAlexander, P | |
| 700 | 1 | _aKlein-Gitelman, M S | |
| 773 | 0 |
_tLupus _gvol. 12 _gno. 8 _gp. 600-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1191/0961203303lu430oa _zAvailable from publisher's website |
| 999 |
_c12715673 _d12715673 |
||